Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:1081 (5 November), doi:10.1136/bmj.331.7524.1081
| The first 150 words of the full text of this article appear below. |
EDITORThe title and interpretation of the EVAR trial results in the POEM are misleading and incorrect.1 Mortality figures were quoted both as aneurysm related and all cause deaths. The 30 day mortality was 1.7% in the EVAR group, which is significantly lower than 4.7% in the open repair group. Surprisingly, the POEM somehow interpreted 30 day mortality to be less than 1% for both groups, which is clearly an error. The confidence intervals (odds ratio 0.35, 95% confidence interval 0.16 to 0.77, P = 0.009) make type I error unlikely. If preintervention deaths are added to the figures 30 day mortality was calculated at 3.5% for endovascular repair and 7.1% for open surgery.2
The advantage of endovascular repair is sustained at four years, with 4% aneurysm related deaths in the EVAR group compared with 7% in the open repair group. This confers a 3% absolute reduction in aneurysm
Jeremy Crane, specialist registrar
j.crane@imperial.ac.uk
Regional Vascular Unit, St Mary's Hospital, London W2 1NY
Meryl Davies, specialist registrar, Nick Cheshire, professor of vascular surgery
Regional Vascular Unit, St Mary's Hospital, London W2 1NY